Health Care · Surgical & Medical Instruments & Apparatus

CARL CARLSMED, INC. SEC Filings & Insider Trading Activity 2026

company
CIK 179454633 filings
Russell 2000

CARL at a glance

CARLSMED, INC. (CARL, SEC CIK 1794546) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and Form 4 insider filings as recently as November 4, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), CARLSMED, INC. (CARL) reported revenue of $50.5 million (up 85.9% from FY2024) and a net loss of $29.6 million. Diluted EPS was -$2.12.
  • As of September 30, 2026, 18 institutional investment managers tracked by SignalX reported holding CARLSMED, INC. (CARL) shares worth $24.1 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Bertolini Jeffrey on November 3, 2026 of 747 shares at $15.15 per share.
  • In the last 90 days, CARL insiders reported 0 open-market purchases ($0) and 4 open-market sales ($29K) on Form 4, a net sale of $29K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$50.5M
+85.9% vs prior year
Insiders · 90 days
0 buys · 4 sells
Net −$29K
13F holders
18 funds
$24.1M · −1 vs prior quarter
Latest 8-K
Nov 10, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: proprietary aprevo platform for personalized spine fusion surgical implants using AI-driven surgical planning software
  • New: 2025 launch of FDA-cleared aprevo cervical spine fusion technology and personalized cervical plating solutions
  • Strategic shift: July 2025 IPO converted all preferred stock to common, enhanced equity capital structure and reclassified warrants to equity
  • Quantitative: cash and short-term investments grew to $109.9M in 2025 from $40.2M in 2024, revenue increased $50.5M (+86%)
  • Noteworthy: executed a 1-for-5.58 reverse stock split in July 2025 concurrent with IPO and significant equity recapitalization

Management Discussion & Analysis

  • No revenue, segment, or profitability details disclosed in this MD&A excerpt
  • Risks highlighted on liquidity due to loan covenants and uninsured cash deposits exposure
  • No dividends planned; future returns depend solely on stock price appreciation
  • Potential dilution from future equity issuances per 2025 Equity Incentive and Employee Stock Purchase Plans
  • Forward risks: regulatory compliance costs, internal control requirements, stock price volatility, and acquisition integration uncertainties

AI summary of the CARL 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes to previously disclosed Annual Report risk factors
  • Business operations vulnerable to unidentified risks and uncertainties
  • Financial condition and cash flows could be negatively affected by realized risks
  • Investment value exposed to adverse business, operational, and financial outcomes

Management Discussion & Analysis

  • Quarterly revenue $21.6M, up 64.9% YoY from $13.1M, driven by higher lumbar and cervical procedure volume
  • Gross margin 77.3% vs 75.9% YoY, aided by lower contract-manufacturer fees and digital production efficiencies
  • Worst profitability metric: operating margin negative 58.9% vs negative 69.1% YoY, with net loss $12.2M vs $8.5M
  • Cash, restricted cash, investments and securities $80.3M, with $15.6M debt outstanding at quarter-end
  • Nine-month operating cash outflow $29.0M, investing outflow $21.7M, primarily marketable-security purchases of $23.6M

AI summary of the CARL 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 10, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results announced for quarter ended September 30, 2026
  • Full results and investor-relevant metrics available in Exhibit 99.1 press release

Item EX-99.1: Item EX-99.1

  • Q3 revenue $21.6M, up 65% year over year, signaling strong adoption of Carlsmed’s AI-enabled spine platform
  • Full-year revenue guidance raised to $78M-$80M from $74M-$78M, implying over 56% midpoint growth
Filed Sep 30, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • CFO Leo Greenstein departed September 25, 2026 without accounting or internal-control disagreements
  • Separation package includes $500,000 cash, pro-rated 2026 incentive, COBRA for 12 months, and accelerated equity vesting

Item EX-99.1: Item EX-99.1

  • Richard Heppenstall appointed CFO effective immediately, replacing Leo Greenstein after three years
  • Heppenstall brings nearly 30 years across healthcare, life sciences, and technology, including CFO experience at ZimVie and Breg

Item 7.01: Regulation FD Disclosure

  • Appointment of Mr. Heppenstall as Chief Financial Officer announced on September 28, 2026
  • CFO transition adds new financial leadership, potentially affecting reporting, capital strategy and investor communications
Filed Sep 8, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Jeffrey Bertolini appointed Chief Operating Officer effective September 8, 2026
  • Internal promotion from Senior Vice President, Operational Excellence, supporting operational continuity

Item EX-99.1: Item EX-99.1

  • Jeff Bertolini promoted to Chief Operating Officer, effective immediately
  • Leadership change elevates operations executive with prior SI-BONE, NuVasive, and US Surgical experience

Item 7.01: Regulation FD Disclosure

  • Bertolini appointed Chief Operating Officer, adding senior operational leadership
  • Appointment may affect execution, scaling, and operating discipline

AI summaries of CARL 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for CARL

Don't miss the next CARL filing

  • Alerts as it files. A push when CARL files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut CARL, by share count.
  • Ask anything. An AI agent that reads every CARL filing and answers with sources.

CARL alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Bertolini JeffreyMNov 3, 2026-
Bertolini JeffreySellNov 3, 2026$15.15
Bertolini JeffreyMNov 3, 2026$5.92
Bertolini JeffreyMOct 30, 2026$2.23
Bertolini JeffreySellOct 30, 2026$15.80
Bertolini JeffreyMOct 30, 2026-
Bertolini JeffreySellOct 5, 2026$14.39
Bertolini JeffreyMOct 5, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$27.2M$50.5M
Gross Profit-$20.0M$38.0M
Operating Income--$24.1M-$30.6M
Net Income--$24.3M-$29.6M
Gross Margin-73.8%75.3%
Op. Margin--88.8%-60.5%
Net Margin--89.3%-58.7%
Balance Sheet
Total Assets-$51.8M$130.1M
Equity-$46.1M-$70.6M$98.9M
ROE-34.3%-30.0%
Per Share
EPS-$-6.11$-2.12
Cash Flow
Operating CF--$25.5M-$29.0M
CapEx-$180K$642K

Source: XBRL data in CARLSMED, INC. (CARL)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate CARL share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
CARL shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202618$24.1M
Q2 202619$18.0M
Q1 202616$9.7M
Q4 202515$14.2M
Q3 202515$12.4M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 83 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

CARL filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 10, 2026Analysis
8-KNov 10, 2026Analysis-
4Nov 4, 2026--
4Nov 2, 2026--
4Oct 6, 2026--
4Oct 1, 2026--
4Sep 30, 2026--
8-KSep 30, 2026Analysis-
4Sep 15, 2026--
4Sep 10, 2026--
8-KSep 8, 2026Analysis-
10-QAug 5, 2026Analysis
8-KAug 5, 2026Analysis-
4Jun 22, 2026--
4Jun 22, 2026--
4Jun 22, 2026--
4Jun 22, 2026--
8-KJun 3, 2026Analysis
10-QMay 5, 2026Analysis
8-KMay 5, 2026Analysis-
4Mar 4, 2026--
10-KFeb 25, 2026Analysis
8-KFeb 25, 2026Analysis-
4Jan 30, 2026-
4Jan 30, 2026-

Related Health Care companies

All Health Care →

CARL SEC filings: frequently asked questions

Are CARL insiders buying or selling?

In the last 90 days, CARLSMED, INC. (CARL) officers, directors and 10% owners reported no open-market purchases and 4 open-market sales worth $29,305 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold CARL stock?

As of September 30, 2026, the largest CARLSMED, INC. (CARL) holders among the 13F filers tracked by SignalX were BlackRock ($8.2 million), Vanguard Capital Management LLC ($4.0 million), D.E. Shaw & Co ($2.1 million), State Street Corp ($1.9 million), AQR Capital Management ($1.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was CARL's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), CARLSMED, INC. (CARL) reported revenue of $50.5 million (up 85.9% from FY2024) and a net loss of $29.6 million. Diluted EPS was -$2.12. The figures come from the XBRL data in the 10-K.

What did CARL report in its latest 8-K?

CARLSMED, INC. (CARL) filed an 8-K on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for quarter ended September 30, 2026.

What are the latest CARL SEC filings?

CARLSMED, INC. (CARL) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and a Form 4 insider filing on November 4, 2026.

What is CARL's SEC CIK number?

CARLSMED, INC. (CARL)'s SEC Central Index Key (CIK) is 1794546. EDGAR lists every CARL filing under that number.

Ask anything about CARL

The research agent reads CARL's filings, financials, insider trades and 13F holders, then answers with sources.